PT786257E - Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas - Google Patents

Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas

Info

Publication number
PT786257E
PT786257E PT96117264T PT96117264T PT786257E PT 786257 E PT786257 E PT 786257E PT 96117264 T PT96117264 T PT 96117264T PT 96117264 T PT96117264 T PT 96117264T PT 786257 E PT786257 E PT 786257E
Authority
PT
Portugal
Prior art keywords
variants
glycosilaca
tissular
therapeutic properties
properties improved
Prior art date
Application number
PT96117264T
Other languages
English (en)
Inventor
William F Bennett
Nicholas F Paoni
Bruce Alan Keyt
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT786257E publication Critical patent/PT786257E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT96117264T 1992-06-03 1993-05-28 Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas PT786257E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89421392A 1992-06-03 1992-06-03

Publications (1)

Publication Number Publication Date
PT786257E true PT786257E (pt) 2003-12-31

Family

ID=25402765

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96117264T PT786257E (pt) 1992-06-03 1993-05-28 Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas

Country Status (20)

Country Link
US (1) US5612029A (pt)
EP (2) EP0786257B1 (pt)
JP (1) JP3559559B2 (pt)
AT (2) ATE155816T1 (pt)
AU (1) AU664469B2 (pt)
CA (1) CA2129660C (pt)
DE (3) DE69333127T2 (pt)
DK (2) DK0643772T3 (pt)
EE (1) EE03128B1 (pt)
ES (2) ES2203668T3 (pt)
FI (1) FI117940B (pt)
GE (1) GEP20012448B (pt)
GR (1) GR3024806T3 (pt)
HK (2) HK1000449A1 (pt)
IL (1) IL105883A (pt)
LU (1) LU90800I2 (pt)
NL (1) NL300050I2 (pt)
NZ (1) NZ253556A (pt)
PT (1) PT786257E (pt)
WO (1) WO1993024635A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013385A2 (en) * 1993-11-12 1995-05-18 Gilead Sciences Thrombin mutants
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (de) * 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
WO1997038123A1 (en) * 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
KR100649043B1 (ko) 1999-11-04 2006-11-27 제넨테크, 인크. 플라스미노겐 활성화제에 대한 역상 고성능 액체크로마토그래피 분석법
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
CN1578650A (zh) * 2001-11-06 2005-02-09 马克西姆医药公司 治疗感染性疾病的组合物
PL371760A1 (en) * 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
JP2009507467A (ja) * 2005-06-02 2009-02-26 アベスタゲン リミテッド 生物工学処理形態の組織プラスミノーゲン活性化因子の生成方法
WO2007030652A2 (en) * 2005-09-08 2007-03-15 University Of Virginia Patent Foundation Methods and compositions for growing adipose stem cells
EP2010117A4 (en) * 2006-04-12 2010-12-01 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR ADHESION INHIBITION
JP2009533458A (ja) * 2006-04-14 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー 神経系の可塑性を媒介する分子経路の同定および変調
CA2661012C (en) 2006-08-29 2019-03-19 Genentech, Inc. Method of treating stroke with thrombolytic agent
KR20090086066A (ko) * 2006-10-06 2009-08-10 유니버시티 오브 버지니아 페이턴트 파운데이션 당뇨성 창상 치유에 유용한 방법 및 조성물
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
KR100834561B1 (ko) 2006-12-08 2008-06-02 가톨릭대학교 산학협력단 크링글 도메인 1 및 2로 이루어진 비-글리코실화 재조합단백질, 그 제조 방법 및 이를 포함하는 조성물
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
EP2289541A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
CN104602701B (zh) * 2012-07-05 2019-04-16 哈达斯特医疗研究服务和开发有限公司 作为抗纤维蛋白溶解剂的纤维蛋白溶酶原活化剂的突变体
EP2928480B1 (en) 2012-12-05 2019-09-25 National Jewish Health Treatment for airway cast obstruction
CN103159860B (zh) * 2013-04-07 2014-09-24 旭华（上海）生物研发中心有限公司 重组组织型纤溶酶原激活剂及其制备方法与用途
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
CN107073292B (zh) * 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物
KR102633644B1 (ko) 2017-02-03 2024-02-05 액티코어 바이오테크 항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
JP2020520386A (ja) 2017-05-16 2020-07-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 急性虚血性脳卒中の処置のための方法及び医薬組成物
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
EP3806833A1 (en) 2018-06-15 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
EP4161579A1 (en) 2020-06-09 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NL8003402A (nl) 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
NO175158C (no) * 1984-10-01 1994-09-07 Genzyme Corp Fremstilling av human livmorsvevplasminogenaktivator med rekombinant-DNA
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK149786A (da) * 1985-04-04 1986-10-04 Beecham Group Plc Proteolytisk enzym
AU596356B2 (en) * 1985-04-22 1990-05-03 Genentech Inc. Novel human tissue plasminogen activator mutants
CA1297008C (en) * 1985-05-28 1992-03-10 Michael D. Johnston Aqueous parenteral solution of tissue-plasminogen activator
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
EP0218112B1 (en) * 1985-09-10 1992-12-09 Eisai Co., Ltd. Composition containing tissue plasminogen activator
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
ES2053449T3 (es) * 1985-12-20 1994-08-01 Upjohn Co Analogos (tpa) de activadores de plasminogeno de tejido.
DE3684680D1 (de) 1985-12-23 1992-05-07 Chiron Corp Peptidplasminogenaktivatoren.
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
EP0293394B2 (en) * 1986-01-31 2003-10-29 Genetics Institute, LLC Novel thrombolytic proteins
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU7090687A (en) 1986-04-02 1987-10-08 Beecham Group Plc Modified tissue-type plasminogen activators
AU7090887A (en) 1986-04-02 1987-10-08 Beecham Group Plc Plasminogen activators modified in first kringle domain
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH0761266B2 (ja) * 1986-07-03 1995-07-05 株式会社ミドリ十字 変異ヒトプロウロキナ−ゼ
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
EP0266032A1 (en) * 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
FI882407A (fi) * 1987-05-22 1988-11-23 Zymogenetics Inc Fibrinolytiska proteiner.
ES2069536T3 (es) * 1987-06-04 1995-05-16 Zymogenetics Inc Analogos del activador del plasminogeno tisular que tienen dominios modificados del factor de crecimiento.
FI882628A (fi) * 1987-06-04 1988-12-05 Zymogenetics Inc T-pa mutaterad genom remplacering av en region bestaoende av tre disulfidbindningar (kringle).
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
KR960015610B1 (ko) * 1987-06-22 1996-11-18 제네틱스 인스티튜트, 인코포레이티드 신규의 혈전붕괴 단백질의 제조방법
EP0365597B2 (en) * 1987-06-30 2005-02-09 Genentech, Inc. Improved processes for the treatment of vascular disease
US4935237A (en) 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
EP0394261A4 (en) * 1987-07-06 1991-09-11 Genetics Institute, Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
AU611932B2 (en) 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
IL88247A0 (en) 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5225540A (en) 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
IL90146A (en) 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8815135D0 (en) * 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
EP0462207B1 (en) * 1989-03-06 2001-02-07 Board Of Regents, The University Of Texas System T-pa mutants resistant to inhibition by their cognate inhibitors
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
DE68927344T2 (de) 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
ATE127839T1 (de) 1990-07-31 1995-09-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Also Published As

Publication number Publication date
GR3024806T3 (en) 1998-01-30
ES2107041T3 (es) 1997-11-16
FI943632A (fi) 1994-10-04
HK1001190A1 (en) 1998-05-29
IL105883A0 (en) 1993-10-20
DE10199044I2 (de) 2006-02-09
HK1000449A1 (en) 2004-03-05
NL300050I1 (nl) 2001-10-01
LU90800I2 (fr) 2001-10-08
EP0786257A1 (en) 1997-07-30
JPH07507448A (ja) 1995-08-24
CA2129660A1 (en) 1993-12-09
DE10199044I1 (de) 2002-02-21
ES2203668T3 (es) 2004-04-16
ATE246000T1 (de) 2003-08-15
EP0643772B1 (en) 1997-07-23
JP3559559B2 (ja) 2004-09-02
DK0643772T3 (da) 1998-02-02
AU664469B2 (en) 1995-11-16
CA2129660C (en) 2005-06-28
EP0786257B1 (en) 2003-07-30
DE69312493D1 (de) 1997-09-04
ATE155816T1 (de) 1997-08-15
DE69333127T2 (de) 2004-05-06
FI117940B (fi) 2007-04-30
NZ253556A (en) 1995-11-27
WO1993024635A1 (en) 1993-12-09
DK0786257T3 (da) 2003-10-06
EE03128B1 (et) 1998-10-15
FI943632A0 (fi) 1994-08-04
IL105883A (en) 2003-04-10
AU4397393A (en) 1993-12-30
EP0643772A1 (en) 1995-03-22
GEP20012448B (en) 2001-05-25
NL300050I2 (nl) 2001-11-01
US5612029A (en) 1997-03-18
DE69312493T2 (de) 1998-01-15
DE69333127D1 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
PT786257E (pt) Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
BE2013C033I2 (pt)
IL80659A (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
IL89500A0 (en) Human tissue plasminogen activator variants and processes
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
DK112290A (da) Vaevsplasminogenaktivator-variant
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse